I made a bogus email and signed up, here is a portion
Analyst Research Report Written by Osman Ghani,
Chartered Financial Analyst
Osman Ghani is a CFA charter-holder and has prior experience in working in Investment banking, corporate finance, and business advisory services. His prior work experience includes working on a number of sectors including Healthcare, manufacturing, IT, real estate, financial services, and business services. He is currently completing his Phd in Finance from the Warwick Business School, University of Warwick, and has a undergraduate and graduate degrees in Accounting and Finance from the London School of Economics. He is also a qualified chartered accountant and a member of the Institute of Chartered Accountants in England and Wales, and he also holds the CAIA designation.
February 24th, 2014
Ticker: NVLX
Recommendation: BUY
Current Price: $0.365 Target Price: $1.24
Highlights:
Nuvilex is a biotechnology company that holds rights to use proprietary cellulose based live cell encapsulation technology aimed at the treatment for cancers and diabetes.
Nuvilex’s Cell-in-a-Box technology alongside the anti-cancer drug ifosfamide has passed Phase 2 of clinical trials and is currently going into phase 3 trials.
The company acquired SG Austria, the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes, which would make the need for daily insulin injections for diabetes sufferers obsolete.
We estimate that the current market price is undervalued and that the expected price should be closer to $1.24. This represents a 240% premium over the current market price.
Business Description
Nuvilex, Inc. (OTC: NLVX), a biotechnology company, holds rights to use a proprietary cellulose-based live-cell encapsulation technology, known as Cell-in-a-Box, for the development of treatments for cancers and for diabetes worldwide. The company was formerly known as eFoodSafety.com, Inc. and changed its name to Nuvilex, Inc. in March 2009. Nuvilex, Inc. was founded in 1996 and is headquartered in Silver Spring, Maryland.
The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer that combines the Cell-in-a-Box technology with the anti-cancer drug ifosfamide. This treatment has completed Phase 1 and 2 clinical trials. The company, through its subsidiary, Medical Marijuana Sciences, Inc., uses constituents of Cannabis in developing treatments for cancer, particularly those that are difficult to treat.
Overview of the Global Pharmaceuticals Industry
According to Market Line, the global pharmaceuticals market grew by 3.5% in 2011 to reach a total value of $782.1 Billion.
According to Market Line, by 2016, the global pharmaceuticals market is expected to have a total value of $971.1 Billion, which represents an increase of 24.2% over the value in 2011.
Within the global pharmaceutical market, the largest segment, representing nearly 42.4% of the total value is the Americas.
Pfizer is the leading company in the global pharmaceutical industry, accounting for nearly 8.7% of the total value.
The market is characterized by strong buyer power, and the ease of market entry is strongly affected by the level of legal and regulatory factors present in each jurisdiction and geographical region.
The global pharmaceuticals market had total revenues of $782.1 Billion in 2011, representing a compound annual growth rate (CAGR) of 4.9% between 2007 and 2011. The European and Asia-Pacific markets grew with CAGRs of 3.1% and 8.8% respectively, to reach values of $224.8 billion and $217 billion in 2011.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.4% for the five year period 2011-2016, which is expected to drive the market to a value of $971.1 billion by 2016. The European and Asia-Pacific markets will grow with CAGRs of 1.8% and 7.4%, and reach values of $246.2 billion and $310.2 billion in 2016.
Figure 1: Global pharmaceuticals market value (in $Billions)
News 
Market Data 
Discover 
AI
